

**IN THE UNITED STATES DISTRICT COURT
WESTERN DISTRICT OF WASHINGTON
AT SEATTLE**

L.B. and M.B., individually and on behalf
of their minor child A.B.; C.M. and A.H.,
individually and on behalf of their minor
child J.M.; and on behalf of others
similarly situated,

Plaintiffs,

v.

Premera Blue Cross,

Defendant.

Case No. C23-0953-TSZ

**STATEMENT OF INTEREST BY THE
UNITED STATES OF AMERICA**

INTRODUCTION

The United States respectfully submits this Statement of Interest to address the effect of the Supreme Court’s recent decision in *United States v. Skrametti*, 145 S. Ct. 1816, 1829 (2025), in this case. See Minute Order (June 20, 2025) (ordering supplemental briefing on *Skrametti*’s “effect, if any”), Dkt. No. 176; 28 U.S.C. § 517 (authorizing the Attorney General to attend to the interests of the United States as a non-party in a suit pending in any court of the United States). The United States has a strong interest in the proper interpretation of federal anti-discrimination law, whether constitutional or statutory.

In light of *Skrametti*, the Court should reconsider its conclusion that “Premera’s medical policy facially discriminates on the basis of sex” (whether “sex” is narrowly or broadly construed), Order 16, Dkt. No. 169, and instead conclude that policies like the one here that classify based on a patient’s age and a treatment’s medical use do *not* discriminate based on sex.

1 **1.** The medical policy at issue provides coverage for certain medically necessary mastectomies or
 2 breast reduction surgeries but excludes coverage for using such procedures to treat gender dysphoria in
 3 patients under 18 years of age. *See* Order 6–7. In other words, it covers the treatments for males and
 4 females equally, but not for minors who have “a diagnosis of gender dysphoria.” *Id.* The medical policy
 5 does not restrict coverage for those treatments on individuals 18 and older; nor does it prohibit coverage
 6 for those procedures to treat minors with diagnoses other than gender dysphoria. *See id.* So a minor patient
 7 may obtain coverage for medically necessary surgeries to treat other conditions, just not to treat gender
 8 dysphoria.

9 Premera justifies its coverage exclusion for mastectomies or breast reductions performed on
 10 minors diagnosed with gender dysphoria based on “(i) a minor’s insufficient maturity ‘to make a truly
 11 informed, educated decision’ and ‘to understand all of the ramifications of such transformation including
 12 its irreversibility,’” and (ii) a “dearth of scientifically-sound studies support[ing]” sex transition surgeries
 13 for minors. *Id.* at 7, 8 (quoting Premera medical policy).

14 This Court concluded that the “policy facially discriminates on the basis of sex,” under either a
 15 “narrow” definition of sex or a “broader” definition of sex. Order 16–20. As to the “narrow” definition,
 16 the Court reasoned that Premera’s policy “treats adolescents differently depending on whether their natal
 17 sex is male or female.” Order 17–18. And as to the “broader” definition, the Court reasoned that the
 18 “policy discriminates on the basis of sex by overtly differentiating between transgender and cisgender
 19 youth or by using the proxy of gender dysphoria.” Order 19–20. In support of both conclusions, the Court
 20 relied heavily on *Kadel v. Fowell*, 100 F.4th 122 (4th Cir. 2024). *See* Order 17–20.

21 **2.** *Skrmetti* addressed a Tennessee law, SB1, under which “a healthcare provider may administer
 22 puberty blockers or hormones to any minor to treat a congenital defect, precocious puberty, disease, or
 23 physical injury; [but under which] a healthcare provider may not administer puberty blockers or hormones
 24 to any minor to treat gender dysphoria, gender identity disorder, or gender incongruence.” 145 S. Ct. at

1 1830–31. The law “does not restrict the administration of [those treatments] to individuals 18 and over.”
2 *Id.* at 1826. Nor does it “fully ban the administration of [the treatments] to minors. A healthcare provider
3 may administer [the treatments] to treat a minor’s congenital defect, precocious (or early) puberty, disease
4 or physical injury”—but not “gender dysphoria, gender identity disorder, and gender incongruence.” *Id.*
5 at 1826–27 (quotation modified).

6 Challengers argued that SB1 discriminates based on sex, in violation of the Fourteenth
7 Amendment’s Equal Protection Clause. The Supreme Court disagreed, rejecting the challengers’
8 arguments that the law “classifies on the basis of sex because its prohibitions reference sex,” that
9 “application of the law turns on sex,” and that the law’s “classifications rest on impermissible [sex]
10 stereotypes.” *Id.* at 1829–32.

11 **3.** Like the law in *Skrametti*, the medical policy here (i) does not restrict coverage for the surgical
12 procedures on “individuals 18 and over,” and (ii) “does not ban fully [the coverage of such procedures
13 on] minors.” *Id.* at 1827. A minor patient may obtain coverage for medically necessary procedures to treat
14 other conditions, but not to treat gender dysphoria. *See id.* (discussing definitions of “congenital defect”
15 and “disease,” and exclusion of “gender dysphoria, gender identity disorder, [and] gender incongruence”
16 from those definitions (quoting the state law at issue)).

17 Therefore, like the state law in *Skrametti*, Premera’s medical policy “incorporates two
18 classifications,” neither of which is a sex classification. *Id.* at 1829. First, the policy “classifies on the
19 basis of age.” *Id.* Patients may obtain coverage for “certain medical treatments to individuals ages 18 and
20 older but not to minors.” *Id.* Second, the policy “classifies on the basis of medical use.” *Id.* Patients may
21 obtain coverage for treatments “to minors to treat certain conditions but not to treat gender dysphoria.”
22 *Id.*

23 “Neither of the above classifications turns on sex.” *Id.* Rather, the medical policy restricts
24 coverage for “administering [treatments] to *minors* for certain *medical uses*, regardless of a minor’s sex.”

1 *Id.* (emphasis in original). The policy’s mere “reference” to sex does not create a sex-based classification.
 2 *Id.* at 1829–30. Nor does the policy’s “application . . . turn[] on sex.” *Id.* at 1829–31.

3 Rather than turning “on whether the[patient’s] natal sex is male or female,” Order 17–19, the
 4 medical policy (like the state law in *Skrmetti*) turns on “the underlying medical concern the treatment is
 5 intended to address,” 145 S. Ct. at 1830. And, “[w]hen properly understood from the perspective of the
 6 indications that [the treatments] treat, [the policy] clearly does not classify on the basis of sex.” *Id.* The
 7 policy “does not prohibit [coverage] for one sex that it permits for the other. Under [the policy], *no* minor
 8 may [obtain coverage for the treatments] to treat gender dysphoria . . . minors of *any* sex may be [obtain
 9 coverage for the treatments] for other purposes.” *Id.* at 1831; *see id.* at 1834–35 (explaining why
 10 “changing a minor’s sex or transgender status does not alter the application of” the challenged state law
 11 and why “sex is simply not a but-for cause of [the law’s] operation”).

12 Likewise, the medical policy “does not exclude any individuals from medical treatments on the
 13 basis of transgender status but rather removes one set of diagnoses—gender dysphoria . . .—from the
 14 range of [coverable] conditions.” *Id.* at 1833. And, because “there is a ‘lack of identity’ between
 15 transgender status and the excluded medical diagnoses,” *id.* at 1834, gender dysphoria does not function
 16 as “a proxy for transgender status,” Order 19–20. *See Skrmetti*, 145 S. Ct. at 1833 (citing *Geduldig v.*
 17 *Aiello*, 417 U.S. 484, 496–97 & n.20 (1974)); *Dobbs v. Jackson Women’s Health Org.*, 142 S. Ct. 2228,
 18 2245–46 (2022) (reasoning that abortion regulations are not sex discrimination, even though abortion is
 19 “a medical procedure that only one sex can undergo”); *Marietta Mem. Hosp. Employee Health Benefit*
 20 *Plan v. DaVita Inc.*, 142 S. Ct. 1968, 1973–74 (2022) (holding that an insurance plan’s reimbursement
 21 limit for dialysis does not violate a statute prohibiting differential treatment of “individuals having end
 22 stage renal disease,” even though dialysis is overwhelmingly used to treat end stage renal disease). In
 23 short, treating gender dysphoria differently is not discrimination based on “transgender status” (let alone
 24 sex), even though only transgender individuals suffer from it.

1 Nor does *Bostock v. Clayton County* “alter [the] analysis.” *Skrmetti*, 145 S. Ct. at 1834 (citing 590
2 U.S. 644 (2020)). Because “changing a minor’s sex or transgender status does not alter the application of
3 [Premera’s policy],” neither sex nor transgender status “is the but-for cause” of a patient’s inability to
4 obtain coverage. *Id.* As the Supreme Court explained in *Skrmetti*, “sex is simply not a but-for cause of
5 SB1’s operation;” rather a patient’s age and a treatment’s medical use are. *Id.* at 1835. So too here.

6 At bottom, it is the medical use of the treatment for minors that matters under Premera’s policy,
7 not the sex of the patient. That is why the treatment would be covered for a patient with a qualifying
8 medical condition, but not for a patient without. Plaintiffs have thus not established any forbidden
9 discrimination.

10 Further driving home the significance of *Skrmetti* on the Court’s prior conclusion, the Supreme
11 Court also has vacated in light of *Skrmetti* the Fourth Circuit’s decision in *Kadel*, on which this Court’s
12 decision primarily relied. *See Folwell v. Kadel*, No. 24-99, 2025 WL 1787687 (U.S. June 30, 2025); Order
13 15–20.

14 4. Lastly, *Skrmetti* recognizes the validity of concerns over providing sex transition treatments to
15 minors like those animating Premera’s medical policy. *See* 145 S Ct. 1835–37. Although not a government
16 policy, and therefore not subject to the same rational-basis review as *Skrmetti* applied, the medical policy
17 nonetheless stems from serious and valid concerns about “protecting minors’ health and welfare.” *Id.* at
18 1836. “[O]ngoing debate among medical experts regarding the risks and benefits associated with
19 administering” the procedures at issue to minors justifies declining to cover those procedures as medically
20 necessary. *Id.* Such “open questions regarding basic factual issues before medical authorities and other
21 regulatory bodies” are a poor fit for judicial resolution in absolute terms under federal anti-discrimination
22 law. *Id.* at 1837.

* * *

As with the state law at issue in *Skrmetti*, the medical policy here may “carr[y] with it the weight of fierce scientific and policy debates about the safety, efficacy, and propriety of medical treatments in an evolving field.” *Id.* Federal anti-discrimination law “does not resolve these disagreements. Nor does it afford [courts] license to decide them as [they] see best.” *Id.* The Court should reconsider its conclusion that “Premera’s medical policy facially discriminates on the basis of sex” (whether “sex” is narrowly or broadly construed), Order 16, and instead conclude that policies like the one here that classify based on a patient’s age and a treatment’s medical use do *not* discriminate based on sex.

Dated this 7th day of July, 2025.

Respectfully submitted,

BRETT A. SHUMATE
Assistant Attorney General

YAAKOV M. ROTH
Principal Deputy Assistant Attorney General

/s/ Charles E.T. Roberts
CHARLES E.T. ROBERTS
Counsel to the Assistant Attorney General
U.S. Department of Justice
Civil Division
950 Pennsylvania Avenue, NW
Washington, DC 20530
(202) 305-1141
Charles.Roberts2@usdoj.gov

Counsel for the United States of America